Abstract: This invention relates to an immunogenic composition comprising a viral vector. The genome of the viral vector comprises a functional origin of replication of a poxvirus, a DNA fragment encoding a non-cleavable gp160, a DNA fragment encoding a signal peptide, and a promoter for expressing DNA fragments in mammalian cells.

Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.

Abstract: This invention relates to plant cells, plants, and seeds expressing a polypeptide having larvicidal activity. In particular, the invention relates to plant cells, plants, and seeds expressing the N-terminal region of a polypeptide toxic against the larvae of Lepidoptera of the Noctuidae family, and preferably against S.littoralis.

Abstract: The invention relates to nucleotidic sequences derived from genomes of the HIV-1 type virus, or from genomes of the HIV-2 type virus, or of the SIV type virus, and their applications, especially as oligonucleotidic initiators of implementation of an (in vitro) method for the diagnosis of the infection of an individual by a virus of the HIV-1 and/or HIV-2 type.

Abstract: The invention relates to a nucleic acid fragment derived from the Mycobacterium tuberculosis genome, characterized in that it contains one of the sequences I, II, III and IV, defined in the following manner:I: a sequence chosen from one of the sequences A to H:A: 5'-CCCGCGGCAAAGCCCGCAGGACCACGATCG-3' (SEQ ID NO. 1)B: 5'-CGACCCGCCAGCCCAGGATCCTGCGAGCGT-3' (SEQ ID NO. 2)C: 5'-GGCGGGTCCAGATGGCTTGCTCGATCGCGT-3' (SEQ ID NO. 3)D: 5'-GTTGGCGGGTCCAGATGGCTTGCTCGATCG-3' (SEQ ID NO. 4)E: 5'-TCAAAGGGTTTGACAAATTAATGATTGGTC-3' (SEQ ID NO. 5)F: 5'-TCGTGTACAAAATGTGGACAAGTA-3' (SEQ ID NO. 6)G: 5'-TCGACGGACGTCGTGACCAGAAGTC-3' (SEQ ID NO. 7)H: 5'-GTCGACACGCCTTCTGCACGGGAAGTCCTT-3' (SEQ ID NO.

Abstract: A novel human immunodeficiency virus type 1 (HIV-1) isolate, designated lymphadenopathy-associated virus strain MAL, or LAV.sub.MAL, was molecularly cloned and characterized. Nucleotide sequence analysis demonstrated that the viral genome of LAV.sub.MAL is 9229 nucleotides long. This retrovirus contains the canonical gag, pol, and env genes, as well as ancillary genes encoding Vif (or Q), Vpr (or R), Tat (or S), and Nef (or F). This virus differs significantly, at both the nucleotide and amino acid sequence levels, from prototypical HIV isolates (e.g., HTLV-III, LAV.sub.BRU, and ARV). DNA fragments corresponding to the various gene products and regulatory regions are disclosed. These fragments are useful, inter alia, as probes in diagnostic assays and for the generation of recombinant proteins.

Abstract: The invention relates to a protein VanB involved, in Gram-positive bacteria, in resistance to glycopeptides, particularly to vancomycine, said resistance being of the type inducible by the vancomycine and non-inducible by teicoplanine. The invention also relates to the utilisation of fragments of nucleotides of the gene van B for the detection of resistances to glycopeptides.

Abstract: The inventors disclose nucleic acids of HIV-2 encoding the entire envelope glycoprotein and peptide regions thereof. Also described are purified and cloned nucleic acids having the entire HIV-2 genome. The nucleic acids can be used to produce polypeptides corresponding to the HIV-2 envelope gene or peptides from specific regions of the HIV-2 envelope gene. Uses in hybridization assays are also disclosed.

Abstract: A recombinant vector capable of replicating in Gram positive bacteria and containing: a) a nucleotide concatenation I of Bacillus thuringiensis with a size of about 2.6 kb between sites BalI-HpaI, or any fragment included in said concatenation as long as its allows replication of the recombinant vector when under the control of functional promoter in Gram positive bacteria, or any sequence which hybridizes with the complementary sequence of concatenation I or the above mentioned fragment under highly stringent conditions, and b) at least on DNA sequence of interest inserted in phase with the above mentioned concatenation.

Abstract: The invention relates to a fragment of nucleic acid characterized in that it comprises a nucleotide sequence selected from: (A) the sequence SEQ ID No. 1; (B) the sequences of one or more bases; (C) fragments of the said sequences (A) and (B); (D) sequences complementary to the said sequences (A), (B), and (C); and (E) the sequences which hybridize with the sequences (A),(B), and (C). The corresponding peptide sequences are also disclosed. A nucleic acid fragment of the invention may be used as a primer or probe, particularly in a method for diagnosing a genetic anomaly linked to the Kallmann syndrome.

Abstract: A method for modifying a wild strain of an entero-invasive Shigella to produce a modified strain of Shigella that can be used for making a vaccine against the wild strain of Shigella. The genome of the wild strain of Shigella is transformed so that it cannot substantially invade cells of a human host and cannot spread substantially within infected cells and from infected to uninfected cells of the host and cannot produce toxins which will kill substantial numbers of the host's infected, as well as uninfected, cells. A first gene of the wild strain of Shigella, coding for a protein necessary for the Shigella to invade cells of the host, and a second gene, coding for a protein necessary for the Shigella to spread within infected cells and between the infected and uninfected cells of the host, are mutagenized.

Abstract: The invention relates to a method for generating structural and functional diversity in a peptide sequence by randomly deleting and inserting nucleotides in a nucleotide sequence which codes for the peptide sequence. This method may be carried out by transfecting a cell preparation with vectors allowing expression of the Rag-1 and Rag-2 genes and optionally the terminal deoxynucleotidyl transferase gene, as well as with a vector including the nucleotide sequence which codes for the peptide sequence.

Abstract: An antigenic composition against S. mansoni comprising an 8 kD peptidic fragment associated with a suitable vehicle, the 8 kD peptidic fragment being obtained by controlled proteolysis using V8 protease of a 28 kD protein obtained from S. mansoni is described.

Abstract: A variant of a LAV virus, designated LAV.sub.ELI and cable of causing AIDS. The cDNA and antigens of the LAV.sub.ELI virus can be used for the diagnosis of AIDS an pre-AIDS.

Abstract: The present invention relates to a process for determining the quantity of a DNA fragment of interest in a sample wherein:1) a standard DNA fragment can be amplified with the same oligonucleotide primers is added to the sample to be analyzed containing the DNA fragment of interest, the standard DNA fragment and the fragment of interest differing in sequence and/or in size by not more than 10%,2) the DNA fragment of interest and the standard fragment are coamplified with the same primers, preferably to saturation of the amplification of the DNA fragment of interest,3) one or more labeled oligonucleotide primer(s), specific for the DNA fragment of interest and the standard fragment and different from the primers of step 2), is/are added to the reaction medium obtained in step 2), so that, after denaturation of the DNA, said primer(s) hybridize(s) with said fragments at a suitable site in order that an elongation with the DNA polymerase generates labeled DNA fragments of different sizes and/or sequences or with

Abstract: The cytA gene encoding the 28 kDa polypeptide of Bacillus thuringiensis israelensis crystals was disrupted in the 72 MDa resident plasmid by in vivo recombination. The absence of the 28 kDa protein in B. thuringiensis israelensis did not affect the crystallization of the other toxic components of the parasporal body. However, the absence of the 28 kDa protein did abolish the hemolytic activity of B. thuringiensis serovar israelensis crystals. The mosquitocidal activity of the 28 kDa protein-free crystals did not differ significantly from the wild-type crystals.

Abstract: Mycobacterium tuberculosis protein having a molecular weight of 28 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.

Abstract: The invention relates to human papillomaviruses HPV, particularly to HPV-DNAs isolated from papillomaviruses HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, HPV-23, HPV-24, HPV-28, HPV-29, HPV-31, HPV-32, HPV-IP2 and HPV-IP4. The invention also relates to DNA capable of hybridizing with the HPV-DNAs or fragments thereof, to kits containing distinct groups of probes containing one or more of these HPV-DNAs or fragments thereof, and to procedures for detecting and identifying HPV in tissue.

Abstract: The complete nucleotide sequence of a proviral molecular clone of the lymphadenopathy-associated virus, LAV, was ascertained. Recombinant phage clones were isolated from a genomic library of LAV-infected human T-lymphocyte DNA. The insert of recombinant phase .lambda.J19 was sequenced according to the dideoxy chain termination method. In addition to the retroviral structural genes gag, pol, and env, a novel open reading frame (ORF) was identified in the 3' region of the viral genome and designated ORF-R. The ORF-R coding region, which has subsequently been renamed nef, encodes a 206 amino acid protein that slightly overlaps the 3' end of the env gene and the 5' portion of the U3 region of the viral long terminal repeat (LTR). Nucleic acids encoding this protein and the precise amino acid sequence of the Nef are disclosed in this application. These products are useful for the generation of immunological reagents to facilitate the detection of LAV.

Abstract: Nucleic acid fragments derived from the HHV6 virus genome, vectors containing said fragments, and their use in the diagnosis of infections involving this virus.